Chinese Innovative Drug and CRO Stocks Surge; CanSino Hits 20% Limit Up

The breadth of the move — spanning vaccine makers, CRO services and biologics suppliers rather than a single name — suggests this is a sector-level repricing of Chinese biotech risk, not an isolated catalyst. That matters because CRO and innovative drug names are among the most rate- and sentiment-sensitive parts of the China equity complex. Whether the rally broadens beyond ChiNext concept baskets into larger-cap pharma, or fades as a one-day momentum trade, is the open question.